glp 1 covered by kaiser GLP-1 medications are changing the conversation around weight loss — but they are not the whole story., “The secret to their success wasn’t one drug.”, In this episode of PermanenteDocs Chat, Alex Kaiser Permanente Glp 1 2025

Short-chain fatty acids (SCFAs) produced by gut bacteria through activation of the G protein-coupled free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41) induce GLP-1 Secretion [159]

Thus, in the context of pharmacotherapeutic use of modern GLP-1 RAs and in terms of understanding the cardiovascular effects of such treatment, the biology of the truncated GLP-1 metabolites can be disregarded (Cherney et al., 2021)

Ideally, these medications should be started when Crohn's disease is in remission, with close collaboration between your gastroenterology and diabetes/obesity teams

Despite numerous such groundbreaking discoveries, including identifying the intestine as a source of incretins [56], this practice did not necessarily identify hormones capable of sufficiently lowering body weight

Early Research in Autoimmune Disease & Fibromyalgia What It Shows and Why Its Limited Fibromyalgia: Early Signals, No Conclusions Some observational reports describe symptom improvements (pain, fatigue, opioid use) in people taking GLP-1 medications, but limitations are consistent: non-randomized design, small samples, and confounding from weight loss, sleep, and metabolic improvements

Medicine is finally coming out of the dark ages, and I am so excited for what its been able to do. Understanding Evolution vs